作者
Ivo N van Schaik, Vera Bril, Nan van Geloven, Hans-Peter Hartung, Richard A Lewis, Gen Sobue, John-Philip Lawo, Michaela Praus, Orell Mielke, Billie L Durn, David R Cornblath, Ingemar SJ Merkies, A Sabet, K George, L Roberts, R Carne, S Blum, R Henderson, P Van Damme, J Demeestere, S Larue, C D'Amour, V Bril, A Breiner, P Kunc, M Valis, J Sussova, T Kalous, R Talab, M Bednar, T Toomsoo, I Rubanovits, K Gross-Paju, U Sorro, M Saarela, M Auranen, J Pouget, S Attarian, G Le Masson, A Wielanek-Bachelet, C Desnuelle, E Delmont, P Clavelou, D Aufauvre, J Schmidt, J Zschuentssch, C Sommer, D Kramer, O Hoffmann, C Goerlitz, J Haas, M Chatzopoulos, R Yoon, R Gold, P Berlit, A Jaspert-Grehl, D Liebetanz, A Kutschenko, M Stangel, C Trebst, P Baum, F Bergh, J Klehmet, A Meisel, F Klostermann, J Oechtering, H Lehmann, M Schroeter, T Hagenacker, D Mueller, A Sperfeld, F Bethke, V Drory, A Algom, D Yarnitsky, B Murinson, A Di Muzio, F Ciccocioppo, S Sorbi, S Mata, A Schenone, M Grandis, G Lauria, D Cazzato, G Antonini, S Morino, D Cocito, M Zibetti, T Yokota, T Ohkubo, T Kanda, M Kawai, K Kaida, H Onoue, S Kuwabara, M Mori, M Iijima, K Ohyama, M Baba, M Tomiyama, K Nishiyama, T Akutsu, K Yokoyama, K Kanai, IN Van Schaik, F Eftimov, NC Notermans, N Visser, C Faber, J Hoeijmakers, K Rejdak, U Chyrchel-Paszkiewicz, C Casanovas Pons, M Alberti Aguiló, J Gamez, M Figueras, C Marquez Infante, S Benitez Rivero, M Lunn, J Morrow, D Gosal, T Lavin, I Melamed, A Testori, S Ajroud-Driss, D Menichella, E Simpson, E Chi-Ho Lai, M Dimachkie, RJ Barohn, S Beydoun, H Johl, D Lange, A Shtilbans, S Muley, S Ladha, M Freimer, J Kissel, N Latov, R Chin, E Ubogu, S Mumfrey, T Rao, P MacDonald, K Sharma, G Gonzalez, J Allen, D Walk, L Hobson-Webb, K Gable
发表日期
2018/1/1
期刊
The Lancet Neurology
卷号
17
期号
1
页码范围
35-46
出版商
Elsevier
简介
Background
Approximately two-thirds of patients with chronic inflammatory demyelinating polyneuropathy (CIDP) need long-term intravenous immunoglobulin. Subcutaneous immunoglobulin (SCIg) is an alternative option for immunoglobulin delivery, but has not previously been investigated in a large trial of CIDP. The PATH study compared relapse rates in patients given SCIg versus placebo.
Methods
Between March 12, 2012, and Sept 20, 2016, we studied patients from 69 neuromuscular centres in North America, Europe, Israel, Australia, and Japan. Adults with definite or probable CIDP who responded to intravenous immunoglobulin treatment were eligible. We randomly allocated participants to 0·2 g/kg or 0·4 g/kg of a 20% SCIg solution (IgPro20) weekly versus placebo (2% human albumin solution) for maintenance treatment for 24 weeks. We did randomisation in a 1:1:1 ratio with an interactive voice and web …
学术搜索中的文章
IN van Schaik, V Bril, N van Geloven, HP Hartung… - The Lancet Neurology, 2018